Calgary-based virtual pharmacy PurposeMed is completing its U.S. expansion this month, bringing its popular Freddie service for HIV prevention and treatment to all 50 states.
MedPage Today on MSN
CDC Backs Twice-Yearly Injectable for HIV Prevention
The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...
The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...
Lupin's shares surged by 2.2% following tentative U.S. FDA approval for its generic HIV treatment, Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets. This positions Lupin to enter a ...
President Donald Trump's long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer. Trump's ...
Some congressional Republicans agree with Democrats that the Trump administration’s plan to require prior approvals for some treatments in traditional Medicare would create barriers to care for older ...
Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the innovative ThecaFlex DRx system.
Sensex and Nifty declined about half a per cent each on Wednesday, falling for a fourth straight session. As the focus shifts to the next trading session on Dalal Street, here are a few stocks set to ...
It's been a confusing and fast-changing couple of months for rules about getting a COVID shot. It should be a little easier now, after a panel of vaccine advisers met last week.
10don MSN
Gene editing is being sold on the promise of healthier babies — but what are the ethical concerns?
The race to advance gene editing tech continues, spurred on by starry-eyed Silicon Valley investors, entrepreneurs and even pronatalists. But it is still deeply controversial.
Akzo Nobel: Goldman Sachs, Morgan Stanley, and other entities picked up a 5 per cent stake in Dutch paint maker Akzo Nobel India for nearly ₹765 crore through open market transactions on Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results